Roche Holding

Roche Holding AG Q4FY25 (ROG) – Stable growth supported by new therapies

Highlights of the report

Roche Holding AG Q4FY25 – Roche continues to benefit from a resilient commercial portfolio supported by key growth products such as Vabysmo, Ocrevus, and Xolair, which are helping offset the ongoing erosion of legacy oncology assets facing biosimilar competition.

CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.

 

CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).

 

Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Rogers Corporation engages in the design, development, manufacture, and sale of engineered materials and components worldwide.

We estimate EV/EBITDA of 19.8x and 19.1x for FY24 and FY25, respectively. We estimate P/S of ~5.2x for FY24 and 5.1x for FY25.

In the last 3 months, the stock has given a return of 17.79%, the stock price increased to CHF 362.90 as of Mar 2, 2026, from CHF 308.10 as of Dec 2, 2025.In the past 1 year, the stock delivered a positive return of 21.66%.

 Executive Summary

• CrispIdea Forecast

– Income Statement

– Balance Sheet

– Cash Flow

– Common Size Ratio Analysis

– CrispIdea Segment Forecast

• Valuation & Historical Performance

– P/E Analysis

– CrispIdea Valuation

– Peer Comparison

– Ratio Analysis

– Economic Value-Added Analysis

– Du Pont Analysis

– CrispIdea Forecast Relative to Consensus

– Consensus Momentum

– Segment Performance

– Key Developments

– M&A Deals

• Ownership

• Stock Price Performance

• Crispidea Coverage

Report details

Roche Holding AG Q4FY25 (ROG) – Stable growth supported by new therapies

Price

$216.00

Company Reports

Sector Reports